ROCKVILLE, Md., April 5 /PRNewswire/ -- RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that J. Scott Tarrant has been hired as Chief Business Officer. Having held senior executive positions at both early stage and publicly traded life-science companies, Tarrant brings 20 years of technical sales, marketing and business development experience to the RRD and their clients. Tarrant was previously engaged by RRD to help chart the Company’s growth strategy and implement its asset-centric business model.
RRD International delivers tactical, regulatory-driven product development support to companies and investors in the life sciences industry. Leveraging its in-house strategic and operational expertise, the Company helps clients better plan, manage and execute product development -- enabling companies to reduce costs, achieve rapid proof of concept, and accelerate the value creation curve. RRD International’s asset-centric development model offers investment efficiencies compared to conventional approaches as it enables companies to build product value instead of costly infrastructure as well as mitigate development and execution risk. The Company’s fully integrated development team has successfully completed more than 50 product development engagements with a wide range of organizations.
Prior to joining RRD International, Tarrant held executive and sales management positions at Gene Logic, TherImmune Research Corporation and Nalco Chemical Company. As a partner and co-founder of Catenate, LLC, Mr. Tarrant has worked closely with a number of early stage life science companies, developing and supporting their corporate and business strategies. He also served as Executive Vice President of Global Sales and Marketing for UK-based Xceleron, Ltd and led the formation of its US subsidiary in Maryland.
About RRD International
Founded in 2002, RRD is a strategy-driven product development company. The Company’s development model enables rapid proof-of-concept for biotech and pharmaceutical clients to accelerate value inflection points; reduce costs; and mitigate development as well as execution risk. RRD offers two distinct types of client engagements: TacDev(R) and DevCo(R). The TacDev(R) model adds development bandwidth and expertise for defined products in companies with minimal infrastructure. The DevCo(R) model creates external product development companies where investment is in asset optimization rather than traditional infrastructure. For more information visit www.rrdintl.com. RRD International: Accelerating the Right Development; Creating Lasting Value.
RRD International
